COMPARISON OF TWO TREATMENT REGIMENS, HYBRID THERAPY AND SEQUENTIAL THERAPY FOR TREATMENT OF HELICOBACTER PYLORI IN PATIENTS WITH PEPTIC ULCER DISEASE

HYBRID THERAPY VERSUS SEQUENTIAL THERAPY FOR ERADICATION OF HELICOBACTER PYLORI â?? A RANDOMIZED TRIAL

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2016/04/006881

Enrollment

128

Registered

2016-04-27

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- PEPTIC ULCER DISEASE AND GASTRITIS Health Condition 2: K279- Peptic ulcer, site unspecified, unspecified as acute or chronic, without hemorrhage or perforation

Interventions

Intervention1: HYBRID THERAPY: OMEPRAZOLE 20 MG BID + AMOXICILLIN 1 GM BID FOR FIRST 7 DAYS. AND THEN OMEPRAZOLE 20 MG BID + AMOXICILLIN 1 GM BID + CLARITHROMYCIN 500 MG BID + METRONIDAZOLE 400 MG TID

Eligibility

Inclusion criteria

Inclusion criteria: All consecutive patients with peptic ulcer disease and gastritis with H. pylori infection.

Exclusion criteria

Exclusion criteria: 1.Patients who have received any form of H.pylori eradication therapy in the past. 2.Patients with associated findings in endoscopy such as malignancy, portal hypertensive gastropathy etc. 3.Patients with gastric ulcers confirmed to be malignant by endoscopic biopsy will be excluded

Design outcomes

Primary

Measure	Time frame
COMPARISON OF ERADICATION RATES OF HELICOBACTER PYLORI IN PATIENTS WITH PEPTIC ULCER DISEASE ADMINISTERED WITH HYBRID THERAPY AND SEQUENTIAL THERAPY AFTER SIX WEEKS FOLLOWING COMPLETION THERAPYTimepoint: COMPARISON OF ERADICATION RATES IN PEPTIC ULCER DISEASE PATIENTS ADMINISTERED WITH HYBRID THERAPY AND SEQUENTIAL THERAPY AFTER SIX WEEKS FOLLOWING COMPLETION THERAPY	—

Secondary

Measure	Time frame
TO ASSESS AND COMPARE THE SIDE EFFECTS AND THE PATIENT COMPLIANCE OF THE HYBRID THERAPY VERSUS THE SEQUENTIAL THERAPY IN ERADICATION OF HELICOBACTER PYLORI IN PEPTIC ULCER DISEASE PATIENTSTimepoint: AFTER COMPLETION OF DRUG THERAPY	—

Countries

India

Contacts

Public ContactDr VIKRAM KATE

JIPMER

drvikramkate@gmail.com09843058013

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026